Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2021.08.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The added value of targeting airway hyperresponsiveness by blocking TSLP in the management of severe asthma.
Eur Ann Allergy Clin Immunol
November 2024
Allergy Unit, National Healthcare System, Scilla, Italy.
Airways hyperresponsiveness (AHR) is a pathognomonic event of asthma in which the airways are reactive to various bronchoconstrictor stimuli at 'doses' that normally have no bronchoconstrictor effect in non-asthmatics. AHR is an objective measure of clinical efficacy, and the introduction of biologics revived interest as a marker of disease and its pathophysiologic mechanism. This article aims to discuss the mechanisms of AHR, focusing on the role of epithelial damage and TSLP production, and promote its correct assessment for the evaluation of patients with severe asthma, to predict the risk of exacerbations and outcomes, and the eligibility for treatment with an anti-TSLP agent.
View Article and Find Full Text PDFResponse to Various Biologics in Patients with Both Asthma and Chronic Obstructive Pulmonary Disease.
Respiration
December 2023
Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.
Introduction: Patients can have features of both chronic obstructive pulmonary disease (COPD) and asthma. However, there is still no consensus how to precisely define this patient population. In addition, there are little data on the effectiveness of biologics in these patients.
View Article and Find Full Text PDFTezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma.
Ann Allergy Asthma Immunol
December 2021
Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!